Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03513328
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:35.409264+00:00
Published At
2023-09-15T00:00:00+00:00
Record Updated At
2023-09-15
Results Posted At
2023-09-15
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Bone Marrow Failure Syndrome", "Thalassemia", "Sickle Cell Disease", "Diamond Blackfan Anemia", "Acquired Neutropenia in Newborn", "Acquired Anemia Hemolytic", "Acquired Thrombocytopenia", "Hemophagocytic Lymphohistiocytoses", "Wiskott-Aldrich Syndrome", "Chronic Granulomatous Disease", "Common Variable Immunodeficiency", "X-linked Lymphoproliferative Disease", "Severe Combined Immunodeficiency", "Hurler Syndrome", "Mannosidosis", "Adrenoleukodystrophy"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-09-15"
protocolSection.identificationModule.nctId
"NCT03513328"
protocolSection.identificationModule.officialTitle
"PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2023-09-15"

Study condition terms

  • Bone Marrow Failure Syndrome (protocolSection.conditionsModule.conditions)
  • Thalassemia (protocolSection.conditionsModule.conditions)
  • Sickle Cell Disease (protocolSection.conditionsModule.conditions)
  • Diamond Blackfan Anemia (protocolSection.conditionsModule.conditions)
  • Acquired Neutropenia in Newborn (protocolSection.conditionsModule.conditions)
  • Acquired Anemia Hemolytic (protocolSection.conditionsModule.conditions)
  • Acquired Thrombocytopenia (protocolSection.conditionsModule.conditions)
  • Hemophagocytic Lymphohistiocytoses (protocolSection.conditionsModule.conditions)
  • Wiskott-Aldrich Syndrome (protocolSection.conditionsModule.conditions)
  • Chronic Granulomatous Disease (protocolSection.conditionsModule.conditions)
  • Common Variable Immunodeficiency (protocolSection.conditionsModule.conditions)
  • X-linked Lymphoproliferative Disease (protocolSection.conditionsModule.conditions)
  • Severe Combined Immunodeficiency (protocolSection.conditionsModule.conditions)
  • Hurler Syndrome (protocolSection.conditionsModule.conditions)
  • Mannosidosis (protocolSection.conditionsModule.conditions)
  • Adrenoleukodystrophy (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.